Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Sanofi SA — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $10.46, while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA pays a 5.5% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals.
| MSTZ | SNY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $52.34 |
52-Week Low | $3.50 | $41.33 |
Market Cap | — | $104.83B |
Enterprise Value | — | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ is trading at $11.49, down 6.2% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The stock faces resistance at $12 and support at $11. Financial ratios remain unavailable, limiting fundamental assessment. Recent news highlights ETF performance trends but provides limited direct company insights.
The outlook remains uncertain due to incomplete financial data and mixed technical indicators. Investment opportunity depends on forthcoming financial disclosures, while risks include market volatility and lack of clear fundamental anchors. Current sentiment appears neutral with limited analyst coverage.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
